Fusion oncogenic events are important targets for oncology research, potentially providing ‘druggable’ targets for subsets of cancer patients. We currently provide FactSheets on:

• RET fusion in CRC PDX models, including model response to RET inhibitor treatment, and the development of acquired resistance models
• FGFR3-TACC3 fusion in NSCLC and brain tumor PDX models, as well as bladder cancer Cell Line Derived Xenograft models. The FactSheet includes a wide range of treatment data and development of in vivo and in vitro resistance models